339 related articles for article (PubMed ID: 19114364)
21. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
[TBL] [Abstract][Full Text] [Related]
22. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
23. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
24. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
27. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.
Sanz GF; Saavedra S; Jiménez C; Senent L; Cervera J; Planelles D; Bolufer P; Larrea L; Martín G; Martínez J; Jarque I; Moscardó F; Plumé G; Andreu R; de la Rubia J; Barragán E; Solves P; Soler MA; Sanz MA
Bone Marrow Transplant; 2001 Apr; 27(7):693-701. PubMed ID: 11360108
[TBL] [Abstract][Full Text] [Related]
28. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
29. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Biol Blood Marrow Transplant; 2004 Mar; 10(3):195-203. PubMed ID: 14993885
[TBL] [Abstract][Full Text] [Related]
30. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
31. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
33. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
[TBL] [Abstract][Full Text] [Related]
34. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
36. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
37. [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation].
Yang DL; Han MZ; Feng SZ; Wang M; Zou DH; Wei JL; Yan ZS; Zhou SY; Liu QG; Jiang EL; Huang Y; Wang HH; Zhou Z; Zhai WJ; Yan WW; Han ZC
Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):285-9. PubMed ID: 15182537
[TBL] [Abstract][Full Text] [Related]
38. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study.
Remberger M; Sundberg B
Biol Blood Marrow Transplant; 2009 Aug; 15(8):996-9. PubMed ID: 19589490
[TBL] [Abstract][Full Text] [Related]
39. Comparison between an artificial neural network and logistic regression in predicting acute graft-vs-host disease after unrelated donor hematopoietic stem cell transplantation in thalassemia patients.
Caocci G; Baccoli R; Vacca A; Mastronuzzi A; Bertaina A; Piras E; Littera R; Locatelli F; Carcassi C; La Nasa G
Exp Hematol; 2010 May; 38(5):426-33. PubMed ID: 20206661
[TBL] [Abstract][Full Text] [Related]
40. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
